Key result
Self-reporting cardiovascular stents and grafts face key technological and regulatory barriers to clinical translation.
Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) is a group of heart and vasculature conditions which are the leading form of mortality worldwide. Blood vessels can become narrowed, restricting blood flow, and drive the majority of hearts attacks and strokes. Reactive surgical interventions are frequently required; including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Despite successful opening of vessels and restoration of blood flow, often in-stent restenosis (ISR) and graft failure can still occur, resulting in subsequent patient morbidity and mortality. A new generation of cardiovascular implants that have sensors and real-time monitoring capabilities are being developed to combat ISR and graft failure. Self-reporting stent/graft technology could enable precision medicine-based and predictive healthcare by detecting the earliest features of disease, even before symptoms occur. Bringing an implantable medical device with wireless electronic sensing capabilities to market is complex and often obstructive undertaking. This critical review analyses the obstacles that need to be overcome for self-reporting stents/grafts to be developed and provide a precision-medicine based healthcare for cardiovascular patients. Here we assess the latest research and technological advancement in the field, the current devices; including smart cardiovascular implantable biosensors and associated wireless data and power transfer solutions. We include an evaluation of devices that have reached clinical trials and the market potential for their end-user implementation.
No takes yet. Share an insight, caveat, or question.
Molloy et al. (2021) conducted a review in Cardiovascular disease (in-stent restenosis and graft failure). Self-reporting cardiovascular implantable medical devices (stents/grafts with biosensors) was evaluated. Self-reporting cardiovascular stents and grafts face technological and regulatory obstacles to clinical market translation; no quantitative primary outcomes are reported in this review.
Synapse has enriched 10 related papers. Consider them for comparative context: